On March 9, pharmaceutical company Galderma welcomed guests to the highly-anticipated launch of its new liquid neuromodulator Alluzience.
The event began with a short welcome from Galderma’s head of global business unit, Gerry Muhle. During the introduction, he outlined the history of the company to date, as well as the exciting movements the company aims to make in a few years’ time.
The evening continued with top Galderma key opinion leaders presenting short talks about the new neuromodulator. Plastic surgery registrar Miss Priya Chadha expanded on the innovation of Alluzience, including its improvement on patient psychological wellbeing, its ease of use with ready-to-use liquid formulation and the fact that it has no animal or human derived excipients.
Nurse prescriber Alice Henshaw discussed the product’s precision, whilst aesthetic practitioner Dr Kuldeep Minocha looked into the performance and safety. A large quantity of evidence from clinical studies was used throughout the talks, demonstrating high patient satisfaction, and the safety and tolerability of the product as well as its adverse events and contraindications for use.
The final talk was presented by aesthetic practitioner Dr Yusra Al-Mukhtar who noted the importance of patients’ psychological wellbeing, complete with a video of patients sharing their personal experiences of how aesthetic treatments helped them regain confidence.
Rene Wipperich, general manager at Galderma, said, “We are very proud to have launched our new product in London – it was our pleasure to see the great interest in our innovation. Our launch meeting was attended by more than 250 healthcare practitioners in-person, as well as watched online. Galderma will continue its commitment to bring new scientific solutions to our customers and drive innovation in the future.”
